Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8969121 | 0.91 | ALDH1A1 (0.33) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL3438064 | 0.88 | ALDH1A1 (0.37) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5985311 | 0.86 | — | — | |
| SCHEMBL2338438 | 0.86 | LMNA (0.34) | — | |
| SCHEMBL17607505 | 0.84 | ALDH1A1 (0.34) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL3386897 | 0.83 | LMNA (0.36) | TSHR | |
| SCHEMBL5984199 | 0.81 | — | — | |
| SCHEMBL18608161 | 0.81 | OPRM1 (0.44) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL1970811 | 0.80 | DNM1 (0.38) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL9111527 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987564-B2 | PTPRD inhibitors and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987564-B2 | PTPRD inhibitors and uses thereof | PTPRS, PTPRCAP, PTPRR | ALDH1A1 535/4885TDP1 905/4885TSHR 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.